Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abacavir
Drug ID BADD_D00008
Description Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
Indications and Usage For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
Marketing Status approved; investigational
ATC Code J05AF06
DrugBank ID DB01048
KEGG ID D07057
MeSH ID C106538
PubChem ID 441300
TTD Drug ID D0A4IJ
NDC Product Code 55111-920; 72865-167; 50268-049; 31722-562; 70518-1274; 65862-073; 31722-557; 68084-021; 0904-6874; 64380-717; 69097-514
UNII WR2TIP26VS
Synonyms abacavir | 1592U89 | abacavir sulfate | Ziagen | (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol | abacavir succinate
Chemical Information
Molecular Formula C14H18N6O
CAS Registry Number 136470-78-5
SMILES C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fat redistribution14.08.04.002--Not Available
Retinal toxicity12.03.01.036; 06.09.03.0130.008243%Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Deep vein thrombosis24.01.02.0030.016485%Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Drug resistance08.06.01.0050.026789%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.004121%
Ill-defined disorder08.01.03.049--Not Available
Autoimmune disorder10.04.04.003--
Respiratory tract infection viral22.07.07.002; 11.05.04.003--Not Available
Renal impairment20.01.03.0100.012364%Not Available
Lipohypertrophy14.08.04.009; 23.07.01.005--
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Hyperamylasaemia14.11.01.003--Not Available
Breath sounds abnormal13.15.01.008--Not Available
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.008243%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Sensitisation10.02.01.012; 08.01.05.009--Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.0440.004121%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.028850%Not Available
Liver function test increased13.03.04.031--Not Available
Persistent depressive disorder19.15.01.006--Not Available
Acute haemorrhagic ulcerative colitis24.07.02.060; 07.08.01.0200.004121%Not Available
Graves' disease05.02.02.009; 10.04.08.014; 06.09.04.009--Not Available
Hepatic cytolysis09.01.07.0360.006182%Not Available
HIV-associated neurocognitive disorder19.20.02.010; 17.03.01.009; 11.05.17.011; 10.03.03.010--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene